Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study.

The Journal of antimicrobial chemotherapy - 1 Dec 2017

Cento Valeria, Aragri Marianna, Teti Elisabetta, Polilli Ennio, Bertoli Ada, Foroghi Luca, Barbaliscia Silvia, Di Maio Velia Chiara, Pieri Alessandro, Pace Palitti Valeria, Sarmati Loredana, Parruti Giustino, Andreoni Massimo, Perno Carlo Federico, Ceccherini-Silberstein Francesca

Abstract excerpt

BACKGROUND: Pretreatment evaluation of HCV-infected patients is a complex interplay between multiple clinical and viral parameters, leading to a tailored approach that may bring real-life sustained virological response (SVR) rates close to 98%-99%. OBJECTIVES: As proof-of-concept, we evaluated the efficacy of all-oral direct-acting antiviral (DAA) regimens in patients whose personalization included pre-therapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Precision Medicine

Share to Proof of Concept Study

Share to RNA, Viral

Share to Sustained Virologic Response

Source

Identifiers

PMID: 28961921
DOI: 10.1093/jac/dkx302

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study.PMID 28961921Read ↗

Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.Semantic proximity Read ↗

DAA-based treatment for HIV-HCV-coinfected patients: analysis of factors of sustained virological response in a real-life study.Semantic proximity Read ↗

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapySemantic proximity Read ↗

Baseline resistance-associated substitutions may impact DAA response among treatment failure chronic hepatitis C patients with pegylated interferon and ribavirin in real life.Semantic proximity Read ↗

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.Semantic proximity Read ↗

Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.Semantic proximity Read ↗

The hepatitis C revolution part 1: antiviral treatment options.Semantic proximity Read ↗

Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.Semantic proximity Read ↗

Factors influencing hepatitis C cure in the era of direct-acting antivirals.Semantic proximity Read ↗

Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.Semantic proximity Read ↗

An Increase in the Prevalence of Clinically-Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV SequencesSemantic proximity Read ↗

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.